PDCD1 and cancer: Monoclonal antibody-based immune checkpoints inhibitors (ICIs) such as Pembrolizumab, Nivolumab, Atezolizumab and Durvalumab have been FDA approved to block the PD-1:PD-L1 interactions and have shown successful results in cancer patients [5,6].